Overview

Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Patients With PL

Status:
Not yet recruiting

Trial end date:
2026-01-31

Target enrollment:

Participant gender:

Summary

This is a Phase III, double-blind, placebo-controlled, safety and efficacy study of daily SC metreleptin in subjects with Partial Lipodystrophy.

Phase:

Phase 3

Details

Lead Sponsor:

Amryt Pharma